1. Home
  2. STTK vs ULBI Comparison

STTK vs ULBI Comparison

Compare STTK & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.35

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo Ultralife Corporation

ULBI

Ultralife Corporation

HOLD

Current Price

$5.74

Market Cap

89.9M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
ULBI
Founded
2016
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
89.9M
IPO Year
2020
1992

Fundamental Metrics

Financial Performance
Metric
STTK
ULBI
Price
$3.35
$5.74
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
429.0K
31.8K
Earning Date
11-06-2025
11-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.10
Revenue
$1,000,000.00
$186,530,000.00
Revenue This Year
N/A
$31.30
Revenue Next Year
N/A
$6.24
P/E Ratio
N/A
$57.38
Revenue Growth
N/A
12.94
52 Week Low
$0.69
$4.07
52 Week High
$3.38
$9.52

Technical Indicators

Market Signals
Indicator
STTK
ULBI
Relative Strength Index (RSI) 72.56 47.95
Support Level $2.82 $5.53
Resistance Level $3.29 $5.94
Average True Range (ATR) 0.23 0.28
MACD 0.00 0.05
Stochastic Oscillator 93.75 42.35

Price Performance

Historical Comparison
STTK
ULBI

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: